Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products |
Namgung, Mi-Ae
(College of Oriental Mediicine, Kyunghee University)
Chang, Yoo-Sung (College of Oriental Mediicine, Kyunghee University) Jeong, Seung-Gi (College of Oriental Mediicine, Kyunghee University) Kim, Jin-Seung (College of Oriental Mediicine, Kyunghee University) Yoon, Sung-Woo (College of Oriental Mediicine, Kyunghee University) Jang, Ki-Young (College of Oriental Mediicine, Daejeon University) Yoo, Hwa-Seung (College of Oriental Mediicine, Daejeon University) Jung, Myeon-Woo (Drug Metabolism Team, National Institute of Toxicological Research, KFDA) Lee, Sung-Ho (Korea University Medical Center) Kim, Sung-Hoon (College of Oriental Mediicine, Kyunghee University) |
1 | 중화인민공화국위생부, 중약신약임상연구지도원칙, 제2집, 1995 |
2 | Food and Drug Administration, Guidance for industry: significant scientific agreement in the review of health claims for conventional foods and dietary supplements, USA, 1999 |
3 | Anthony.J.Neal.ClinicalOncology3rdedition(basic principles and practice), Oxford University Press, 123-137, 2003 |
4 | 왕영염주편, 중의내과학, 상무인서관, 391-397, 2000 |
5 | 周雄順 外. 藥論惡性腫瘤 放化療後的中醫治療原則, 浙江中醫學院學報, 3:11-12, 1990 |
6 | 양유걸주편, 암증종류의론의화정선, 약군문화사업공사, 408- 415, 1989 |
7 | 浙江中醫學院學報編輯委員會, 腫留-中醫藥防治癌症病人放化療副反應, 浙江中醫學院學報, 6:49, 1986 |
8 | WHO, QOL(quality of life) user manual : facet definitions and response scales, WHO, 601-671. 1998 |
9 | 蔡德政. 黨蔘花粉治療放療化療所致造血功能障碍26例療效初步觀察, 中醫雜誌 11:25-26, 1987 |
10 | EORTC, Study on Quality of Life Version 3.0, EORTC, 1995 |
11 | 金光 外. 中藥防治腫瘤化療毒副反應509例臨床觀察, 陜西中醫, 11:485, 1990 |
12 | Han, J.Y., Kim, H.K., Choi, B.G., Moon, H., Hong, Y.S., Lee, K.S. Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC). Jpn J Clin Oncol. 28(12):749-753. 1998 DOI ScienceOn |
13 | 徐悔文. 降逆湯防治腫瘤化療消化道反應三十七例, 浙江中醫雜誌, 1:5, 1989 |
14 | 양검유등. 현대종류학, 상해의과대학, pp 425-428, 1993 |
15 | Center for Drug Evaluation and Research(CDER), Department of Health and Human Services Food and Drug Administration, Guidance for industry : botanical drug products, 2004 |
16 | EMEA, Guideline On The Clinical Assessment Of Fixed Combinations Of Herbal Substances / Herbal Preparations, Doc.Ref.EMEA/HMPC/166323, 2005 |
17 | Bishop, Fienberg & Holland. Discrete Multivariate Analysis, MIT Press, p 103, 1975 |
18 | 식품의약품안전청, 천연물신약연구개발촉진법 제 2조, 법률제6165호 신규제정 2000 |
19 | Katsutoshi Terasawa, Kampo, tokyo, K.K. Standard Mcintyre, 22, 1993 |
20 | 이천림, 질변통계, 양유근 주편:위생통계학 제2판, 북경 인민위생출판사, 207-209, 1990 |
21 | Wesley, M.N., Wesley, R.A. Biostatics in clincial trials In: Textbook of oncology., Williams and Wilkins, pp 346-348, 1986 |
22 | 식품의약품안전청. 임상시험의 전반적인 고려사항, 생물의약품평가자료집 13, 2004 |
23 | Center for Drug Evaluation and Research(CDER) & Center for Biologics Evaluation and Research(CBER), Guidance for industry : clinical trial endpoints for the approval of cancer drugs and biologics, 2005 |
24 | Rosner. Fundamentals of Biostatistics, 5th Edition, 39, 2000 |
25 | 대한의학협회 분과학회협의회 편저: 의학총서 암의 진단과 치료, 여문각, 23-35, 1992 |
26 | Abrial, S.C., Penault-Llorca, F., Delva, R., Bougnoux, P., Leduc, B., Mouret-Reynier, M.A., Mery-Mignard, D., Bleuse, J.P., Dauplat, J., Cure, H., Chollet, P. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 3:1-9, 2005 DOI |
27 | Bertil Axelsson, Tryck & Medier. The incurable cancer patient at the end of life, Uppsala University, 2001 |
28 | Vencent T DeVita. Cancer principle and practice of oncology 4th ed., JB LIPPINCOTT Company, 678-887, 1993 |
29 | 정수유. 중약신약임상연구 지도원칙 :시행(中藥新藥臨床硏究指導原則:試行), 중국의약기술출판사, 제024754호, 207-224, 2004 |
30 | 서울대 의과대학, 선경인더스트리 연구소: 제3세대 백금착제 항암제 신약개발 보고서, 보건복지부, 1994 |
31 | National Cancer Institute(NCI), Cancer Clinical Trials: The Basic Workbook, National Institutes of Health(No.02-5050), 2001 |
32 | Martin, D. Abeloff, Clinical oncology, Churchill Livingstone Inc. 1999 |
33 | 중화인민공화국위생부, 중약신약임상연구지도원칙, 제1집, 1993 |
34 | 중화인민공화국위생부, 중약신약임상연구지도원칙, 제3집, 1997 |
35 | 한국식품안전청 의약품안전국. 임상시험통계지침, 의약 65625-13553호, 2000 |
36 | WHO/EDM/TRM, General guidelines for methodologies on research and evaluation of traditional medicine, 2000 |
37 | 鞠永棕編. 고오스 藥理學, 서울, 汎文社, 701-710, 1986 |
38 | 이용구, 통계학원론, 율곡출판사, 199-222, 1991 |